FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2409735402> ?p ?o ?g. }

• W2409735402 endingPage "6009" @default.
• W2409735402 startingPage "6002" @default.
• W2409735402 abstract "Abstract Purpose: Abiraterone may suppress androgens that stimulate breast cancer growth. We conducted a biomarker analysis of circulating tumor cells (CTCs), formalin-fixed paraffin-embedded tissues (FFPETs), and serum samples from postmenopausal estrogen receptor (ER)+ breast cancer patients to identify subgroups with differential abiraterone sensitivity. Methods: Patients (randomized 1:1:1) were treated with 1,000 mg/d abiraterone acetate + 5 mg/d prednisone (AA), AA + 25 mg/d exemestane (AAE), or exemestane. The biomarker population included treated patients (n = 293). The CTC population included patients with ≥3 baseline CTCs (n = 104). Biomarker [e.g., androgen receptor (AR), ER, Ki-67, CYP17] expression was evaluated. Cox regression stratified by prior therapies in the metastatic setting (0/1 vs. 2) and setting of letrozole/anastrozole (adjuvant vs. metastatic) was used to assess biomarker associations with progression-free survival (PFS). Results: Serum testosterone and estrogen levels were lowered and progesterone increased with AA. Baseline AR or ER expression was not associated with PFS in CTCs or FFPETs for AAE versus exemestane, but dual positivity of AR and ER expression was associated with improved PFS [HR, 0.41; 95% confidence interval (CI), 0.16–1.07; P = 0.070]. For AR expression in FFPETs obtained &lt;1 year prior to first dose (n = 67), a trend for improved PFS was noted for AAE versus exemestane (HR, 0.56; 95% CI, 0.24–1.33; P = 0.19). Conclusions: An AA pharmacodynamic effect was shown by decreased serum androgen and estrogen levels and increased progesterone. AR and ER dual expression in CTCs and newly obtained FFPETs may predict AA sensitivity. Clin Cancer Res; 22(24); 6002–9. ©2016 AACR." @default.
• W2409735402 created "2016-06-24" @default.
• W2409735402 creator A5005973748 @default.
• W2409735402 creator A5007579054 @default.
• W2409735402 creator A5013077058 @default.
• W2409735402 creator A5019547742 @default.
• W2409735402 creator A5030978586 @default.
• W2409735402 creator A5031915637 @default.
• W2409735402 creator A5032818174 @default.
• W2409735402 creator A5040832210 @default.
• W2409735402 creator A5045467858 @default.
• W2409735402 creator A5050466082 @default.
• W2409735402 creator A5060580174 @default.
• W2409735402 creator A5060983890 @default.
• W2409735402 creator A5061759413 @default.
• W2409735402 creator A5061992932 @default.
• W2409735402 creator A5069672625 @default.
• W2409735402 creator A5069748055 @default.
• W2409735402 creator A5071432873 @default.
• W2409735402 creator A5071553983 @default.
• W2409735402 creator A5074465614 @default.
• W2409735402 creator A5077726848 @default.
• W2409735402 creator A5080782271 @default.
• W2409735402 date "2016-12-15" @default.
• W2409735402 modified "2023-10-12" @default.
• W2409735402 title "Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer" @default.
• W2409735402 cites W1987117672 @default.
• W2409735402 cites W2010080966 @default.
• W2409735402 cites W2044791827 @default.
• W2409735402 cites W2059843298 @default.
• W2409735402 cites W2074619468 @default.
• W2409735402 cites W2111976640 @default.
• W2409735402 cites W2116483002 @default.
• W2409735402 cites W2129440404 @default.
• W2409735402 cites W2137853125 @default.
• W2409735402 cites W2159464222 @default.
• W2409735402 cites W2168108459 @default.
• W2409735402 cites W2213568616 @default.
• W2409735402 cites W2597533030 @default.
• W2409735402 cites W42450160 @default.
• W2409735402 doi "https://doi.org/10.1158/1078-0432.ccr-15-2452" @default.
• W2409735402 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27267854" @default.
• W2409735402 hasPublicationYear "2016" @default.
• W2409735402 type Work @default.
• W2409735402 sameAs 2409735402 @default.
• W2409735402 citedByCount "16" @default.
• W2409735402 countsByYear W24097354022017 @default.
• W2409735402 countsByYear W24097354022018 @default.
• W2409735402 countsByYear W24097354022019 @default.
• W2409735402 countsByYear W24097354022020 @default.
• W2409735402 countsByYear W24097354022021 @default.
• W2409735402 countsByYear W24097354022023 @default.
• W2409735402 crossrefType "journal-article" @default.
• W2409735402 hasAuthorship W2409735402A5005973748 @default.
• W2409735402 hasAuthorship W2409735402A5007579054 @default.
• W2409735402 hasAuthorship W2409735402A5013077058 @default.
• W2409735402 hasAuthorship W2409735402A5019547742 @default.
• W2409735402 hasAuthorship W2409735402A5030978586 @default.
• W2409735402 hasAuthorship W2409735402A5031915637 @default.
• W2409735402 hasAuthorship W2409735402A5032818174 @default.
• W2409735402 hasAuthorship W2409735402A5040832210 @default.
• W2409735402 hasAuthorship W2409735402A5045467858 @default.
• W2409735402 hasAuthorship W2409735402A5050466082 @default.
• W2409735402 hasAuthorship W2409735402A5060580174 @default.
• W2409735402 hasAuthorship W2409735402A5060983890 @default.
• W2409735402 hasAuthorship W2409735402A5061759413 @default.
• W2409735402 hasAuthorship W2409735402A5061992932 @default.
• W2409735402 hasAuthorship W2409735402A5069672625 @default.
• W2409735402 hasAuthorship W2409735402A5069748055 @default.
• W2409735402 hasAuthorship W2409735402A5071432873 @default.
• W2409735402 hasAuthorship W2409735402A5071553983 @default.
• W2409735402 hasAuthorship W2409735402A5074465614 @default.
• W2409735402 hasAuthorship W2409735402A5077726848 @default.
• W2409735402 hasAuthorship W2409735402A5080782271 @default.
• W2409735402 hasBestOaLocation W24097354021 @default.
• W2409735402 hasConcept C121608353 @default.
• W2409735402 hasConcept C126322002 @default.
• W2409735402 hasConcept C134018914 @default.
• W2409735402 hasConcept C143998085 @default.
• W2409735402 hasConcept C2775832370 @default.
• W2409735402 hasConcept C2775860665 @default.
• W2409735402 hasConcept C2775930923 @default.
• W2409735402 hasConcept C2776551883 @default.
• W2409735402 hasConcept C2777176818 @default.
• W2409735402 hasConcept C2777899217 @default.
• W2409735402 hasConcept C2780192828 @default.
• W2409735402 hasConcept C2781197716 @default.
• W2409735402 hasConcept C2908647359 @default.
• W2409735402 hasConcept C530470458 @default.
• W2409735402 hasConcept C55493867 @default.
• W2409735402 hasConcept C61367390 @default.
• W2409735402 hasConcept C71924100 @default.
• W2409735402 hasConcept C84606932 @default.
• W2409735402 hasConcept C86803240 @default.
• W2409735402 hasConcept C99454951 @default.
• W2409735402 hasConceptScore W2409735402C121608353 @default.
• W2409735402 hasConceptScore W2409735402C126322002 @default.
• W2409735402 hasConceptScore W2409735402C134018914 @default.

• next